help_outline Skip to main content
HomeNews List

News / Articles

Search News / Articles

News

Published On 11/23/2022
More than 200 accredited angel investors registered for this first-of-its-kind hybrid Investor Capital Expo co-hosted by Keiretsu Forum South-East and Mercer University. This multi-session showcase gave an in-person and virtual stage to 12 US-based growth stage companies seeking funding (see list below). In addition to presenting companies, Pat Gouhin, Executive Director of the Angel Capital Association, presented the event’s Keynote on the state of Angel Investing in 2022. The Expo concluded with an entrepreneurial workshop curated for students, faculty, and investors on the art and science of securing funding through angel investors.
Read More navigate_next
Published On 10/11/2022
The 2021 HALO report issued by the Angel Resource Institute again ranked Keiretsu Forum the #1 most active investment group nationwide by number of deals. Additionally, the report notes that the Keiretsu Forum network is extremely active with deals in almost every state & region of the US, finishing #1 or #2 in every region except New York. On Tuesday, November 1, 2022, Keiretsu Forum South-East and the City of Richardson’s Innovation Quarter will co-host an informational event to explore the benefits of establishing a Keiretsu Forum Chapter in the greater Dallas area.
Read More navigate_next
Published On 4/22/2022
A newly minted sponsor of the Southeast Life Sciences AdvanSE 2022 conference, Keiretsu Forum’s Mid-Atlantic and South-East regions have committed to providing pitch opportunities to both regions for the winners of the PitchRounds competition.
Read More navigate_next
Published On 4/18/2022
Keiretsu Forum Mid-Atlantic is proud to announce the next speaker in their Thought Leadership series- Matthew Le Merle. He is the Co-founder and Managing Partner of Keiretsu Capital and Managing Partner of Blockchain Coinvestors. Launched in 2014, Blockchain Coinvestors’ goal is to provide broad coverage of the emerging unicorns and fastest growth blockchain companies and crypto projects.
Read More navigate_next
Published On 2/7/2022
Keiretsu Forum is the world’s largest angel investor network. According to Pitchbook’s 2020 Annual Global League Tables, Keiretsu Forum is the U.S. Region’s #1 and #2 Most Active in Late and Early Stage investments. Headquartered in Philadelphia, Keiretsu Forum Mid-Atlantic and Southeast reports record breaking deal flow and investments for the second consecutive year.
Read More navigate_next
Published On 1/28/2022
Keiretsu Forum Mid-Atlantic Regional President, Howard Lubert welcomed four new Due Diligence Fellows this month. These graduate students hail from local universities and were selected from applicants who want to work with Keiretsu Forum angel investor members to advance the early-stage, entrepreneurial ecosystem in this region.
Read More navigate_next
Published On 1/4/2022
Seneca Therapeutics has raised $5 million in a debt
financing deal that will enable the immunotherapy
company to advance its experimental solid cancer
treatments.
Founded in 2018 by Paul Hallenback, Seneca has
now raised about $8 million since its inception.
Read More navigate_next
Published On 11/24/2021
More than 1,750 accredited angel investors registered for the second annual virtual Investor Capital Expo hosted by Keiretsu Forum. This bi-coastal, multi-session showcase gave the virtual stage to 21 US-based growth-stage companies seeking funding. In addition to presenting companies, a lineup of premier keynotes and panels presented an educational track diving into the hottest trends in angel investing heading into 2022.
Read More navigate_next
Published On 11/8/2021
Keiretsu Forum, a global investment community of accredited private equity angel investors, venture capitalists and corporate/institutional investors, today announced it will host its 2021 Virtual East Coast Investor Capital Expo, the premier gathering of the Investor Capital Community. During this year’s Expo, 24 companies will present to more than 2,000 attendees, fostering collaboration among angel groups, family offices, corporate partners, and the larger investment community.
Read More navigate_next
Published On 11/8/2021
More than one thousand accredited angel investors will attend the second annual virtual Investor Capital Expo hosted by Keiretsu Forum, showcasing 24 US-based growth-stage companies seeking funding. Investor Capital Expo takes place November 10-11 (West Coast-focus) and November 17-18 (East Coast-focus). In addition to presenting companies, a lineup of premier keynotes will present an educational track diving into the hottest trends in angel investing heading into 2022.
Read More navigate_next
Published On 4/14/2021
Setting a standard for most active investors three years running,
Keiretsu Forum, the world’s largest angel investor network, today announced Pitchbook has released its 2020 Annual Global League Tables highlighting Keiretsu Forum as the U.S. Region’s #1 and # 2 Most Active Late and Early Stage investors.

Impressively on the Global Stage, Keiretsu Forum was ranked the # 2 Most Active, Early and Late Stage investors.Keiretsu Capital, the exclusive worldwide fund partner of Keiretsu Forum, continues to be a top-tier funder of late stage investment deals in the network.
Read More navigate_next
Published On 2/5/2021
Deal activity increases 16%. Life Science, Medical Devices, Environmentally-Sensitive/Aware Materials/Devices, and solution-driven Technologies attract the most capital

SAN FRANCISCO, CA—Keiretsu Forum, the world’s largest angel investor network ranked #1 by Pitchbook as “Most active investors early stage” and “Most active investors late stage,” today announced it achieved a record 314 fundings into seed, early-stage and late-stage companies in 2020. Despite the pandemic, Keiretsu Forum saw deal activity increase 16% compared to 2019, with Life Science, Medical Devices, Environmentally-Sensitive/Aware, and solution-driven Technologies attracting the most capital.
Read More navigate_next
Published On 8/6/2020
HOUSTON, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced the continued enhancement of the intellectual property (IP) portfolio governing its lead investigational drug candidate, seclidemstat. The European Patent Office (EPO) recently announced that the European Patent EP2744330, exclusively licensed to Salarius from the University of Utah Research Foundation, was issued on July 15, 2020.

The European patent covers composition of matter and methods of use for seclidemstat, a potent reversible inhibitor of the LSD1 enzyme which is currently the subject of a Phase 1/2 clinical trial for Ewing sarcoma, a rare pediatric bone cancer, and a Phase 1/2 trial in advanced solid tumors (AST). Salarius intends to validate this European patent in several important EU countries.
Read More navigate_next

Press Releases & Articles

Published On 11/7/2022
In just over a week, premier companies primarily in technology and life sciences seeking funding will be showcased at the Keiretsu Forum’s 10th Annual Investor Capital Expo on November 16th and 17th on the Atlanta Campus of Mercer University. All accredited investors, venture capitalists, and family offices are invited to attend in-person or virtually.

There are several trends affecting the industry that will be a focus at the show, underscored by our keynote speaker, Pat Gouhin, CEO of the Angel Capital Association.
Read More navigate_next
Published On 10/3/2022
Keiretsu Forum Global Investor Network Ranked #1 Angel Investor Group, U.S. Region, by The Angel Resource Institute 2021 HALO Report based on the number of deals - lauds Keiretsu Forum’s both local and global footprint.
Read More navigate_next
Published On 8/22/2022
The Accelerator Venture Partners (AVP) family of Funds, a Philadelphia area venture fund group focused on exceptional early-stage companies announces initial investments through its AVP 2022 FastTrak Fund.

The AVP FastTrak Fund was brought to the region by Howard Lubert, Area President of Keiretsu Forum Mid-Atlantic and South-East, as a tool for new angel investors to quickly diversify their portfolios. The limited partners invest up to $100,000 per deal as a “first-money-in” to jump-start a company’s funding round after completing the rigorous Keiretsu Forum due diligence process.
Read More navigate_next
Published On 3/15/2022
Although many businesses continue to recover from the impacts of the pandemic, the emerging business ecosystem measured record growth in 2021. Overall venture capital investment in the United States almost doubled year-over-year to $329.9 B in 2021 (according to Pitchbook’s Interactive Global Tables, March 4, 2022).
Read More navigate_next
Published On 1/4/2022
Accelerator Venture Partners (AVP), a Greater Philadelphia based early-stage venture fund, announces the addition of a new general partner, Scott MacColl. Scott is the Founder of MacColl Strategic Advisors. The firm provides consulting services for insurers, reinsurers, and intermediaries focused on Surety and credit-related insurance products domestically and internationally. Scott joins AVP for an opportunity to parlay his experience in collaboration with knowledgeable accredited investors to offer expertise in a variety of areas critical to making informed investment decisions.
Read More navigate_next
Published On 1/19/2021
Venture Capital investment set records in 2020. Early-stage investment hit a trough in Q2, but swift action by the angel community and tailwind opportunities created by COVID-19 fueled a rebound in Q3 and Q4. Locally, 2020 was a banner year for Keiretsu Forum's Mid-Atlantic (K4-MA) and South-East (K4-SE) Regions booking record growth.

US Venture Capital investing set records in 2020, surpassing surprising performance in 2018 (Source: PitchBook Venture Monitor). Investors deployed just over $156B and liquidated over $290B in exit value, with massive exits happening in Q3 and Q4. Early-stage investments in 2020 did not see the same bounce back but did see a healthy increase in the last two quarters of the year.
Read More navigate_next
Published On 1/15/2021
Keiretsu Forum Mid-Atlantic announced the launch of a new chapter in Princeton, New Jersey. Keiretsu Forum is the world's largest and most active investment community of early-stage accredited angel investors with 53 Chapters across 3 continents, including the newly minted North Jersey Chapter.

"Since 2011, Keiretsu Forum Mid-Atlantic Chapters have provided resources, mentoring, and funding to entrepreneurs while delivering accredited investor members with the highest quality deal flow as well as exclusive educational and networking opportunities" says Howard Lubert, Co-Founder. "We are delighted to have Harvey Homan take the lead as President of this new Chapter."

Dr. Homan comes to the organization with a passion for innovation and entrepreneurship, a rich history in life-science startups, and the experience to lend guidance to Founders and Funders. Dr. Homan will be joined in the stewardship of this Chapter by Host Sponsor, Morgan Lewis, & Bockius.
Read More navigate_next
Published On 11/30/2020
Three sessions, six weeks, 36 high-quality investment opportunities describes this year's Keiretsu Forum Investor Capital Expo. The virtual event attracted over 900 registered accredited investors from 50 angel groups, investors from 100+ Family Offices, corporate partners, and keynotes from leading experts. To date, featured companies have more than 2,000 indications of investment interest. By all measures, it was a very successful Expo; for three investors, it was an exceptional Expo.

To encourage constructive feedback to presenting companies, investors who submit their 'gold sheet' feedback forms for all three sessions were eligible to win a $25,000 investment in the Most Valued Company Special Purpose Vehicle. The winners were drawn at random and are:

Paul Gianneschi, member of the Atlanta Chapter, Ashley Hancock, member of the Atlanta Chapter, and Brad Kollmyer, member of 1 month of the Vancouver Chapter
Read More navigate_next
Published On 11/30/2020
Virion Therapeutics, developing novel T cell based treatments for cancers and infectious diseases using the world's first genetically encoded checkpoint inhibitor, was one of three companies named a "Most Valued Company" at the virtual Keiretsu Forum Investor Capital Expo which showcased 36 premier growth-stage companies primarily in life sciences and technology. Nearly 50 angel groups, investors from 100+ Family Offices, corporate partners, and hundreds of accredited investors attended the Expo.

Virion was hand-picked by hundreds of attending angel investors as a stand-out innovator amongst a group of highly touted, entrepreneurial companies from U.S. and Canada.
Read More navigate_next
Published On 11/30/2020
Nearly 50 angel investment groups, investors from 100+ Family Offices, corporate partners, and hundreds of accredited investors from across the globe attended the Keiretsu Forum Investor Capital Expo. Over the course of the three-day virtual event, 36 premier growth-stage companies were presented. To date, more than 2,000 indications of interest from investors have been received. Philadelphia's own, Howard Lubert, Co-Founder of Keiretsu Forum Mid-Atlantic and South-East, was the mastermind behind the virtual event and worked tenaciously with the Keiretsu Forum North American team to customize an event platform that could accommodate the needs of a global investor forum.
Read More navigate_next
Published On 11/30/2020
The biggest trends in angel investing, plus 36 premier late-stage companies primarily in technology and life sciences seeking funding, are the showcase at the virtual Investor Capital Expo that kicked-off its first session October 14. The next two live sessions take place October 28 and November 11th.
Read More navigate_next

Blog

Published On 1/7/2020
COLLEGE PARK, Md., Dec. 19, 2019 /PRNewswire/ — gel-e, Inc., announced today that the Company has changed its name to Medcura. The corporate name change is effective [...]
Read More navigate_next
Published On 12/21/2019
Keiretsu Forum Mid-Atlantic is well-positioned as an angel investment group; we get to see many of the best deals in our space. I’ve done a survey of angel investing trends for 2020 and have been gratified to see that these trends are reflected in the deals we review each month.
Read More navigate_next
Published On 12/21/2019
HaptX announced a $12 million fundraising round Thursday, allowing the Seattle startup to develop its next generation of virtual reality gloves and robotics.
Read More navigate_next
Published On 12/4/2019
PORTFOLIO COMPANY, LAURENT PHARMACEUTICALS, RECEIVES A CAD 2.7M FINANCING FROM BIOMED PROPULSION FUND
Read More navigate_next
Published On 11/12/2019
The article was written by Dr. Merom Klein PhD + Dr. Louise Yochee Klein PsyD
Read More navigate_next
Published On 11/12/2019
Authored by: Radu Pislariu, MD, Laurent Pharmaceuticals | President & CEO
Read More navigate_next
Published On 11/12/2019
UBIQD EARNS THE 2019 NEW PRODUCT INNOVATION AWARD FROM FROST & SULLIVAN FOR ITS QUANTUM DOT-ENABLED UBIGRO™ GREENHOUSE FILM
Read More navigate_next
Published On 11/8/2019
Howard Lubert, co-founder of Keiretsu Forum Mid-Atlantic, will address entrepreneur and industry leaders at the Baruch S. Blumberg Regional Biotech Conference as they explore how early-stage companies can get investors to 'Show Me The Money'
Read More navigate_next
Published On 10/20/2019
The over 200 angel investors participating in the Keiretsu Forum Mid-Atlantic's Investor Capital Expo selected OctoNexus as the winner of the Stephen M. Goodman Most Valued Company Award for 2019. This honor has advantages prior winners in funding and development.
Read More navigate_next
Published On 10/7/2019
One year after winning the Stephen M Goodman Award at the 6th Annual Keiretsu Forum Angel Capital Expo, Carmell Therapeutics’ President, and CEO, Randy Hubbell reflects on what the honor meant to the Company and how they leveraged the award to achieve significant milestones. As a reminder, Carmell Therapeutics is a clinical-stage biotechnology company focused on the development and commercialization of regenerative medicine solutions to accelerate bone and soft tissue healing. Randy’s pitch at last year’s event earned him the votes from attending accredited investors to receive this distinguished award.
Read More navigate_next
Published On 8/19/2019
INDIGO Biosciences announces appointment of Mark McLoughlin to the Board of Directors. Mr. McLoughlin brings four decades of healthcare industry experience to the Company's Board.
Read More navigate_next
Published On 3/19/2020
EXPECT ROUGH QUARTERS. BUT IN THE LONG TERM, VENTURE INVESTMENT COULD BENEFIT FROM STOCK MARKET CRASH
Read More navigate_next
Published On 3/4/2020
THE ONLY 10 SLIDES YOU NEED IN A PITCH
Read More navigate_next
Published On 2/28/2020
Keiretsu Forum South-East has entered into a resource collaboration with the Georgia Institute of Technology. The objective of this collaboration is to further innovation, entrepreneurship and technology transfer in the South-East region. This educational relationship provides entrepreneurial-minded faculty and students of Georgia Tech with exposure to well-prepared and experienced executives in a role-model context.
Read More navigate_next
Published On 7/26/2019
PORTFOLIO COMPANY, UBIQD, ANNOUNCES NOVEL QUANTUM DOT OPTICAL FIBER TECHNOLOGY THAT DELIVERS EXTRA LIGHT TO THE LOWER CANOPY OF PLANTS
Read More navigate_next
Published On 7/26/2019
PORTFOLIO COMPANY, PITTMOSS, $1.75 MILLION FUNDRAISING – BRIAN P SCOTT FILED JUL 25 FORM D
Read More navigate_next
Published On 7/17/2019
PORTFOLIO COMPANY, ASTARTE MEDICAL, APPOINTS GIULIA KENNEDY TO BOARD OF DIRECTORS
Read More navigate_next
Published On 7/17/2019
Carmell Therapeutics, a pioneer in the development and commercialization of innovative Plasma-based Bioactive Materials (PBMs) to accelerate bone and soft tissue healing, has named Wendy F. DiCicco to the Company’s Board of Directors.
Read More navigate_next
Published On 7/12/2019
Join the Bradbury Science Museum and the Los Alamos Creative District for a special ScienceFest edition of Science On Tap.
Read More navigate_next
Published On 7/12/2019
New View Surgical, Inc., an emerging medical device company developing proprietary imaging and access technologies for minimally invasive surgery, announced that it closed its Series A Financing Round at $2.5 million. The financing was over-subscribed due to investor demand. New View Surgical will deploy the financing to complete the development of its VisionPort™ System, expand the company’s intellectual property portfolio and submit a 510(k) U.S. Food and Drug Administration (FDA) filing.
Read More navigate_next
Published On 7/1/2019
ExpressCells, Inc. (ExpressCells), a private genetic engineering company that creates advanced cell lines for drug discovery, today announced that it has completed the first close of its Series A financing round. The Rowan Innovation Venture Fund and Keiretsu Forum Mid-Atlantic are jointly leading this round.
Read More navigate_next
Published On 6/17/2019
More than 380,000 babies are born prematurely in the United States every year. And the first 1,000 days of life are a critical period for a baby’s growth and brain development, especially for preterm infants. Plus maintaining a healthy gut is critical during this period. And the rapid changes in the microbiome during this period makes it challenging for NICU teams to treat infants with a highly personalized level of care.
Read More navigate_next
Published On 6/10/2019
Like nature, the world of entrepreneurship, venture capital and investment abhors a vacuum.
Read More navigate_next
Published On 6/4/2019
Touch-transmitting Telerobotic Hand to be show cased at Amazon re:MARS
Read More navigate_next
Published On 5/20/2019
Laura R. Gordon, Ph.D. and Ronald C. Kern, Jr., Ph.D. are associates in the Philadelphia office of BakerHostetler. Their practices focus on patent prosecution and client counseling in the life science, biotechnology and pharmaceutical arenas.
Read More navigate_next
Published On 5/13/2019
Astarte Medical, a Yardley, Pa.-based software company in the precision medicine space, announced Tuesday it raised a $5 million Series A round led by Keiretsu Forum MidAtlantic.
Read More navigate_next
Published On 5/2/2019
Organizers of ASPIRE 2019 invite Keiretsu Forum Mid-Atlantic members to attend this event in Philadelphia on June 12, 2019, which will collect the region’s leading investors, deal-makers, and entrepreneurs.
Read More navigate_next
Published On 4/26/2019
According to a report released this week by PitchBook-NVCA Venture Monitor, the first quarter of 2019 shows signs that this year is shaping up to be another very active year for investing, and Keiretsu Forum is leading early-stage funding.
Read More navigate_next
Published On 3/29/2019
UBIQD WINS 2019 SXSW PITCH COMPETITION, HYPER-CONNECTED COMMUNITIES CATEGORY
Read More navigate_next
Published On 3/6/2019
Life sciences/biotech companies are a significant economic driver in the greater Philadelphia area, with an estimated 1,200 businesses employing nearly 50,000 people in 2017, according to the Greater Philadelphia Life Sciences Report, 2017. In my experience, there is significant growth within the early stage life sciences sector; most will need to seek capital to grow to an inflection point. Much financing is through angel investors; what used to be a purely venture capital space has opened up to professional angels, primarily through investment groups such as The Keiretsu Forum, the Mid-Atlantic Bio Angels and others.
Read More navigate_next
Published On 2/21/2019
Keiretsu Forum Mid-Atlantic portfolio company, Salarius Pharmaceuticals, negotiated a successful exit in January. Salarius and publicly traded Flex Pharma, Inc (NASDAQ: FLKS) announced that the companies entered into a definitive merger agreement under which Flex Pharma is expected to be renamed Salarius Pharmaceuticals, Inc. and be under the leadership of Salarius’ current management team, led by Chief Executive Officer, David Arthur.
Read More navigate_next
Published On 2/6/2019
Keiretsu Forum is listed as the number #1 “most active global investor by VC deal count” in the PitchBook Global League Tables for the third year in a row.
Read More navigate_next